{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:14:46Z","timestamp":1767204886379,"version":"build-2238731810"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) caused by complement dysregulation, leading to microangiopathic anemia, thrombocytopenia, and acute kidney injury (AKI). Complement over activation typically results from genetic mutations in alternative pathway proteins. The genetic profile varies regionally and influences clinical phenotype and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study in all 27 patients (12 children, 15 adults) diagnosed with aHUS, at \u201cFundeni\u201d Clinical Institute, between January 2017 and January 2025. Median age was 30\u00a0years (range, 1\u201370), 59% female. All patients were treated with anti-C5 monoclonal antibodies and followed for a median of 13\u00a0months (9\u201327).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No patient had a family history of aHUS. Infections were the most common trigger (67%). Although 30% had a history of previous events, the median time from latest event to admission was 30\u00a0days, reflecting late diagnosis and referral, but the median time from admission to treatment was 8\u00a0days. At presentation, 60% of patients required dialysis and all had anemia, but 20% had no thrombocytopenia. AKI was common and the predominant clinical presentation was acute nephritic syndrome. Renal biopsies showed acute-on-chronic TMA with glomerulosclerosis and interstitial fibrosis in 90% and 80% of cases, respectively. Genetic testing revealed CFH\/CFHR variants in 39% and CFI variants in 22% of patients. Anti-C5 therapy led to remission of anemia and thrombocytopenia in about 90% of patients, C3 normalization in 90%, and dialysis independence in 74%. No deaths or serious adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this Romanian aHUS cohort, CFI variants were more frequent than expected, probably reflecting a different geographical distribution. Anti-C5 therapy proved effective and safe. However, limited patient numbers and observational design are study limitations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1683188","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:17:32Z","timestamp":1763356652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Terminal complement inhibition in atypical haemolytic uremic syndrome: a single-centre experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Valentin D.","family":"Mocanu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan M.","family":"Sorohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena G.","family":"Micu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"B\u0103l\u0103nic\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Obri\u015fc\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana A.","family":"Jurubi\u021b\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia A.","family":"Achim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian C.","family":"Lungu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina S.","family":"C\u0103pu\u015f\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Mircescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.5001\/omj.2023.117","article-title":"Epidemiology, management, and outcome of atypical hemolytic uremic syndrome in an Omani cohort","volume":"38","author":"Al Riyami","year":"2023","journal-title":"Oman Med. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1056153","DOI":"10.3389\/fimmu.2022.1056153","article-title":"COVID-19 vaccination and atypical hemolytic uremic syndrome","volume":"13","author":"Bouwmeester","year":"2022","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","article-title":"Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome","volume":"65","author":"Bu","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome","volume":"46","author":"Dragon-Durey","year":"2008","journal-title":"J. Med. Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6036-25","DOI":"10.2169\/internalmedicine.6036-25","article-title":"C3 p.Asp1115Asn variant-associated atypical hemolytic uremic syndrome with spontaneous remission triggered by influenza and COVID-19","volume":"11","author":"Fujino","year":"2025","journal-title":"Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10157-018-1549-3","article-title":"Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome","volume":"22","author":"Fujisawa","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.semdp.2020.01.002","article-title":"A new paradigm for renal thrombotic microangiopathy","volume":"37","author":"Gallan","year":"2020","journal-title":"Seminars Diagnostic Pathology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"J\u00f3zsi","year":"2008","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.23876\/j.krcp.22.010","article-title":"A new pathological perspective on thrombotic microangiopathy","volume":"41","author":"Kim","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.asjsur.2022.07.055","article-title":"Evolution in the diagnosis and treatment of hemolytic uremic syndrome","volume":"46","author":"Liu","year":"2023","journal-title":"Asian J. Surg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrneph.2014.250","article-title":"Podocyte dysfunction in atypical haemolytic uraemic syndrome","volume":"11","author":"Noris","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1011580","DOI":"10.3389\/fimmu.2022.1011580","article-title":"CFH and CFHR structural variants in atypical hemolytic uremic syndrome: prevalence, genomic characterization and impact on outcome","volume":"13","author":"Piras","year":"2022","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/imr.13131","article-title":"Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases","volume":"313","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2023","journal-title":"Immunol. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"14496","DOI":"10.3390\/ijms241914496","article-title":"Underlying genetics of aHUS: which connection with outcome and treatment discontinuation?","volume":"24","author":"Spasiano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"18265","DOI":"10.1038\/s41598-024-68736-6","article-title":"Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective study","volume":"14","author":"Tatematsu","year":"2024","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2020-136278","article-title":"Triggers in patients with atypical hemolytic uremic syndrome: an observational cohort study using a US claims database","volume":"136","author":"Tomazos","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000513009","article-title":"Clinical and genetic characteristics of atypical hemolytic uremic syndrome in children: a Chinese cohort study","volume":"145","author":"Wu","year":"2021","journal-title":"Nephron"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome","volume":"3","author":"Zipfel","year":"2007","journal-title":"PLoS Genet."}],"updated-by":[{"DOI":"10.3389\/fphar.2025.1760223","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1683188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:58:20Z","timestamp":1765447100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1683188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":33,"alternative-id":["10.3389\/fphar.2025.1683188"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1683188","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1683188"}}